Rectal Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Rectal Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources, and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely; blood, either bright red or very dark in the stool; stools that are narrower than usual; general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps; weight loss with no known reason; constant tiredness; and vomiting. Rectal cancer treatment includes surgery, radiation therapy or chemotherapy, or a combination of these approaches.
The Rectal Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Rectal Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 66 molecules, with 65 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Rectal Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Rectal Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Rectal Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adlai Nortye Biopharma Co LtdAkeso Inc
AptaBio Therapeutics Inc
Arcus Biosciences Inc
Ascentawits Pharmaceuticals Ltd
AstraZeneca Plc
BeiGene Ltd
Beijing Konruns Pharmaceutical Co Ltd
Beijing StarMab BioMed Technology Ltd
Bio-Thera Solutions Ltd
BioAtla Inc
Biomimetix JV LLC
Bristol-Myers Squibb Co
CytomX Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Ellipses Pharma Ltd
Erasca Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Genexine Inc
GSK plc
HCW Biologics Inc
HotSpot Therapeutics Inc
Incyte Corp
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Juntendo University Hospital
Kinnate Biopharma Inc
Kortuc Japan LLC
Kronos Bio Inc
LG Chem Ltd
LIfT BioSciences Ltd
Loxo Oncology Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
MiNK Therapeutics Inc
Oncolys BioPharma Inc
OncXerna Therapeutics Inc
Ono Pharmaceutical Co Ltd
PDS Biotechnology Corp
Pieris Pharmaceuticals Inc
Precigen Inc
Privo Technologies Inc
Pyxis Oncology Inc
Revolution Medicines Inc
Shanghai Haihe Biopharma Co Ltd
Shanghai Junshi Biosciences Co Ltd
SN BioScience
SQZ Biotechnologies Co
Starpax Biopharma Inc
Sunho (China) Biopharmaceutical Co Ltd
Suzhou Ruotai Pharmaceutical Technology Co Ltd
Taiho Oncology Inc
Takeda Pharmaceutical Co Ltd
Teon Therapeutics Inc
Transcenta Holding Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Rectal Cancer reports